R
Reidulv Hatlevoll
Publications - 7
Citations - 1498
Reidulv Hatlevoll is an academic researcher. The author has contributed to research in topics: Radiation therapy & Multicenter trial. The author has an hindex of 7, co-authored 7 publications receiving 1474 citations.
Papers
More filters
Journal ArticleDOI
Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer.
K Nygaard,S. Hagen,H S Hansen,Reidulv Hatlevoll,R Hultborn,A Jakobsen,M Mäntyla,H Modig,E Munck-Wikland,B Rosengren +9 more
TL;DR: The results indicate that pre-operative irradiation had a beneficial effect on intermediate term survival, whereas the chemotherapy regime used did not influence survival.
Journal ArticleDOI
Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group.
K. Kristiansen,S. Hagen,T. Kollevold,A. Torvik,I. Holme,M Stat,R. Nesbakken,Reidulv Hatlevoll,M. Lindgren,Arne Brun,S. Lindgren,G. Notter,A. P. Andersen,Kjell Elgen +13 more
TL;DR: Patients in Group 3 deteriorated faster than patients in Groups 1 and 2, and Bleomycin had no positive or negative influence on survival.
Journal ArticleDOI
Oligodendroglioma: incidence and biological behavior in a defined population
Sverre Mørk,Karl-Fredrik Lindegaard,Tore B. Halvorsen,Egil H. Lehmann,Torfinn Solgaard,Reidulv Hatlevoll,Sverre Harvei,Jeremy C. Ganz +7 more
TL;DR: The survival data from this unselected series indicate that cerebral oligodendrogliomas have a less favorable prognosis than has generally been believed.
Journal ArticleDOI
Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma
Karl-Fredrik Lindegaard,Sverre Mørk,Geir Egil Eide,Tore B. Halvorsen,Reidulv Hatlevoll,Torfinn Solgaard,Olav Dahl,Jeremy C. Ganz +7 more
TL;DR: It is indicated that irradiation doses between 40 and 50 Gy were as effective as doses between 50 and 60 Gy in increasing the patients' probability of surviving 5 years after subtotal tumor resection and the lower dose is recommended.
Journal ArticleDOI
Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group.
Reidulv Hatlevoll,Karl Fr. Lindegaard,Steinar Hagen,Kristian Kristiansen,Ragnar Nesbakken,Ansgar Torvik,Jeremy C. Ganz,Olav Mella,Bengt Rosengren,Rolf Ringkjöb,Oddur Arnasson,Sten Lindgren,Marck Lipecki,Gustav Notter,Bo Littbrand,Nils-Erik Säterborg,Gudmundur Benediktsson,Leif Johansson,Bo Spännare,Arne Brun,Anne Kiil Berthelsen,Henning Busch,Erik Grönbæk,Jorgen Rygård,Jens Haase,Eiler Lambrethsen,Steen Midholm,Per Sehested,Mirja Heikkinen,Stig Nyström,Pentti Taskinen,Matti Mäntylä,Kjell Elgen,Ove Aaskoven,Stephen T. De Garis,Rud Hammer Jensen,Ingrid Matheson +36 more
TL;DR: A prospective and randomized trial has been performed in order to evaluate combined modality therapy in patients with astrocytomas grade 3 and 4 as mentioned in this paper, and the results showed practically identical periods of median survival, and no statistically significant differences were observed with regard to performance status, side effects, or complications.